Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nina Besche"'
Autor:
Michael Boettcher, Gerd Mikus, Dietmar Trenk, Hans‐Dirk Düngen, Frank Donath, Nikos Werner, Mahir Karakas, Nina Besche, Dominik Schulz‐Burck, Mireille Gerrits, James Hung, Corina Becker
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 5, Pp 1204-1214 (2022)
Abstract Vericiguat was developed for the treatment of symptomatic chronic heart failure (HF) in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. Guidelines recommend long‐acting nitrates, such a
Externí odkaz:
https://doaj.org/article/802eb1a41f814307a5c64af6075f3e09
Autor:
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Pim Gal, Gerd Mikus, Dietmar Trenk, Martin Coenen, Philippe Vieira Pires, Claudia Maschke, Antonios Othon Aliprantis, Nina Besche, Corina Becker
Publikováno v:
American Journal of Cardiovascular Drugs. 23:145-155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12410062f25b14292c7d70a0ce3b4628
https://doi.org/10.1007/s40256-022-00557-2
https://doi.org/10.1007/s40256-022-00557-2
Autor:
Michael Boettcher, Hans‐Dirk Düngen, Frank Donath, Gerd Mikus, Nikos Werner, Petra A. Thuermann, Mahir Karakas, Nina Besche, Tanja Koch, Matthias Gurniak, Corina Becker
Publikováno v:
Clinical pharmacology and therapeutics. 111(6)
Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in adults with symptomatic chronic HF and ejection fraction less than 45%. Guidelines recommend short-act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0154b06d4f1cb4e7b3fca5e92ad8da6
https://pubmed.ncbi.nlm.nih.gov/35258101
https://pubmed.ncbi.nlm.nih.gov/35258101
Autor:
Martin Radtke, Corina Becker, Nina Besche, Mireille Gerrits, Julia Lemmen, Dirk Thomas, Michael Boettcher, Wolfgang Mueck, Michael Gerisch, Maximilian Lobmeyer
Publikováno v:
Clinical Pharmacokinetics
Background Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534). Patients with heart failure often require polypharmacy because of comorbid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4868a371ea6899ea09d0fd298497128c
https://pubmed.ncbi.nlm.nih.gov/32458378
https://pubmed.ncbi.nlm.nih.gov/32458378